Seroquel Poised To Take Market Lead Within Months – AstraZeneca
This article was originally published in The Pink Sheet Daily
AstraZeneca expects Seroquel to surpass Johnson & Johnson's Risperdal in terms of prescription share within the antipsychotic market by the end of the year
You may also be interested in...
The efficacy of AstraZeneca’s quetiapine was established in two 12-week monotherapy trials, revised labeling states. Seroquel’s original bipolar indication was based upon three-week trial data.
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.